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Another Look at Erythromycin
J. L. STRAUGHAN
SUMMARY
The erythromycins are broadly reviewed from a clinical
viewpoint. The antimicrobial spectrum, clinical indications,
pharmacokinetics and toxicity are dealt with. The useful-
ness of erythromycin for respiratory tract infections is
stressed. New evidence to support bactericidal activity of
this antibiotic is noted. There seems little reason to use
the potentially hepatotoxic estolate form of erythromycin.
The safety of the other forms of this antibiotic available in
this country is emphasized.
S. Afr. med. l., 53, 527 (1978).
Tn 1952 erythromycin was discovered among the meta-
bolic products of a strain of Streptomyces erythreus
Waksman, from the fungal growth in a soil sample from
the Philippines.
Hosts of new and allegedly new antibiotics have made
their appearance since 1952, and these newcomers tend
to displace interest in, and familiarity with, the benefits
of some of the older agents still available. In their latest
edition of Antibiotic and Chemotherapy, Garrod et al.'
state that 'Leaving aside the special problem of the hepa-
totoxicity of the estolate, there is no doubt that erythro-
mycin is one of the most innocuous antibiotics in current
use'. As this article hopes to show, it is also one of the
most' useful antibiotics available, especially in general
practice.
WHAT IS ERYTHROMYCIN?
Erythromycin is classified as a macrolide antibiotic. The
word 'macrolide' indicates that it has a macrocyclic lactone
ring in its chemical structure. It is chiefly an antibacterial
agent but is active against other micro-organisms as well.
Marked instability of the basic erythromycin molecule
in an acid environment has led pharmaceutical researchers
to produce derivatives of the parent drug which are more
acid-resistant and better absorbed. Thus, a variety of
forms for oral use are on the market, which make use
of relatively acid-resistant derivatives or acid-resistant
formulations, or both.
WHAT IS THE MECHANISM OF ACTION OF
ERYTHROMYCIN?
Erythromycin inhibits protein synthesis within the cells of
micro-organisms because it binds with the 50S ribosomal
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subunit of the organisms and arrests peptide bond form-
ation.'·4 Thus its primary action is intracellular, and there-
fore effective against most of the clinically important strains
of Mycoplasma, and selectively toxic for micro-organisms
because there is no 50S subunit to the ribosomes of the
human host.
IS ERYTHROMYCIN BACTERIOSTATIC OR
BACTERICIDAL?
The answer to this question is 'both'. Depending on the
organism in question and the concentration of the anti-
biotic that can be attained in its environments, erythro-
mycin can behave bactericidally or bacteriostatically, or
indeed be quite ineffective: The same can be said for
the antibiotic penicillin. The terms bactericidal and bacter-
iostatic are always relative"" At the low dosages recom-
mended for both penicillin V and for erythromycin in
the treatment of rheumatic fever, the antibiotics produce
levels that are lethal (cidal) to the highly susceptible
group A ,B-haemolytic Streptococcus but scarcely affect
other organisms at all - which accounts for the inno-
cuous nature of the prophylaxis.
Elegant studies reported at the 1977 International Con-
gress on Chemotherapy showed that 500 mg of erythro-
mycin stearate administered 3 times a day to adults
suffering from acute upper respiratory infections was
bactericidal in vivo to group A ,a-haemolytic strepto-
cocci, Staphylococcus aureus, Streptococcus pneumoniae
and Haemophilus influenzae.'
WHAT IS THE ANTIMICROBIAL SPECTRUM
OF ERYTHROMYCIN?
Erythromycin is very active against many Gram-positive
cocci, in particular Staphylococcus pyogenes, Diplococcus
pneumoniae, Streptococcus viridans and S. pyogenes. The
penicillinase-producing Staphylococcus strains are also
susceptible to erythromycin.
Of the Gram-positive bacilli, the following are sus-
ceptible to the action of erythromycin: Corynebacterium
diphtheriae, C. minutissimum, Bacillus anthracis, Clostri-
dium tetani, Cl. perfringens (welchii), and Listeria mono-
cytogenes. Of the Gram-negative bacteria, Neisseria
meningitidis, N. gonorrhoeae, Haemophilus influenzae and
Bordetella pertussis are susceptible. Many Brucella spp.
and Yersinia spp. are also susceptible, as is the Fuso-
bacterium fusiforme of Vincent's angina. It has even been
reported that most strains of Escherichia coli and Kleb-
siella are inhibited in the urinary tract, provided the urine
is rendered alkaline by the use of systemic alkalinizers
such as potassium citrate/sodium citrate, etc.' More studies
in this regard would seem to be indicated.
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Recent surveys show that many Bacteroides spp., Trepo-
nema pallidum and the actinomycetes are susceptible to
erythromycin.'" Some rickettsial organisms responsible for
typhus fevers are also susceptible to this antibiotic, as is
Chlamydia. Mycoplasma pneumoniae is highly susceptible
to erythromycin.
FOR WHAT CONDITIONS IS
ERYTHROMYCIN MOST USEFUL?
The efficacy of this antibiotic against so many Gram-
positive cocci and against H. influenzae and Mycoplasma
pneumoniae makes it an excellent respiratory tract anti-
biotic. Thus this antibiotic is recommended for strepto-
coccal tonsillopharyngitis, and for other pharyngeal in-
fections, for sinusitis, otitis media, laryngitis, tracheitis,
and acute bronchitis, and for primary atypical pneumonia.
For persons allergic to penicillin who require an
antibacterial agent with the spectrum of penicillin G or
V, erythromycin is probably the drug of choice, provided
that penetration across the blood-brain barrier is not re-
quired, such as in bacterial meningitis. For the treatment
of rheumatic fever, erythromycin is the drug of choice
after penicillin. For the treatment of soft-tissue infections,
erythromycin can be very useful, especially when peru-
cillinase-producing organisms are involved. A wide selection
of penicillinase-resistant agents is available nowadays, yet
for boils, styes, paronychia, impetigo, cellulitis, etc.,
relatively minor but everyday conditions, this antibiotic
would seem to recommend itself. In the management of
diphtheria, both symptomatic and asymptomatic (carrier),
erythromycin is considered to be a very good choice."
Prostatitis and 'nonspecific' urethritis frequently involve
infection with Chlamydia, and the use of erythromycin
for such conditions might be recommended.
Bacteroides spp., the cause of many anaerobic infections,
are very susceptible to erythromycin. Erythromycin is
highly effective in eradicating the organism involved in
pertussis from the nasopharynx of affected persons and
from carriers.12 A course of 10 days' duration is currently
recommended for paediatric use," although uncontrolled
trials would indicate that 5 days' treatment might be just
as effective." In the treatment of primary syphilis, erythro-
mycin is an acceptable alternative to penicillin. Un-
controlled trials indicate that erythromycin is also very
useful in the treatment of acne requiring antimicrobial
treatment.
WHAT IS KNOWN OF THE PHARMACO-
KINETICS OF ERYTHROMYCIN?
The aspect of pharmacokinetics brings to the fore some
rather more problematical material. Erythromycin for
oral use is available in several forms and formulations in
South Africa: erythromycin base, erythromycin stearate,
erythromycin ethylsuccinate, erythromycin ethylcarbonate,
and erythromycin estolate.
Bio-availability
With regard to bio-availability the following points seem
pertinent: The base is very unstable in an acid medium
and is therefore protected from the gastric juice by apply-
ing various acid-resistant coatings to the tablet and cap-
sule products utilizing the base. Provided that the product
releases its contents satisfactorily in the small bowel, the
erythromycin base will be well absorbed;16,'. however,
wide variations in absorption rate are common when
the base is administered. The stearate is relatively acid-
stable and is dissociated from the base in the small in-
testine, and the active erythromycin is subsequently ab-
sorbed.
The ethylsuccinate and the ethylcarbonate are still more
acid-stable. These forms are virtually tasteless and are
therefore used in paediatric formulations, such as sus-
pensions and sachets. These forms are well absorbed,
chiefly from the small intestine, are absorbed intact and
have to be hydrolyzed systemically. The hydrolysis of
these two esters takes place very rapidly, so these forms
of the antibiotic also give highly acceptable levels of
erythromycin base. It is important to note that only the
erythromycin base demonstrates antimicrobial activity."
Erythromycin estolate, which is tasteless, is well ab-
sorbed from the gut, even in the presence of food, and
is acid-stable, so that good serum levels of the estolate are
found." However, a problem arises with regard to the
rate and degree of hydrolysis that occurs systemically. The
excellent serum levels provided by this form of erythro-
mycin are a reflection of the total level of estolate plus
base, and to date, no entirely satisfactory data are availa-
able to provide an insight into the absolute levels of the
base alone formed in vivo.
This whole topic is still highly contentious and it seems
that we should still be guided by the fact that treat-
ment with the various salts and esters of erythromycin
seems comparable ill terms of efficacy, and that, ex-
cluding toxicity, there would appear to be little reason
for choosing one form rather than another.
Unpublished data suggest that bio-availability differences
among some products of erythromycin available in South
Africa do exist;" this should be considen'd as a cause
for concern.
Distribution
Erythromycin penetrates all body fluids a..d tissues well,
with the important exception of the brain and cerebro-
spinal fluid. The cerebrospinal fluid levels must be con-
sidered inadequate for therapeutic efficacy, especially when
other agents that penetrate the blood-brain barrier more
effectively are available. The levels found in fetal serum
reflect from 5% to 20% of maternal serum levels, while
breast milk levels reflect some 50% of the serum levels.
Concentrations of erythromycin in urine are very low;
2 - 5% of an oral dose finds its way out via the urine.
The efficacy of this antibiotic in, for example, chlamydial
urethritis,'· probably indicates good tissue levels and poor
urine levels.
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A study reported at the 1977 International Congress on
Chemotherapy indicates that erythromycin provides very
good levels in the bronchi and in the bronchial secretions.'"
The study accentuates the value of this antibiotic in
respiratory infections caused by susceptible organisms.
Protein binding is 70 - 90% at the usual therapeutic serum
levels.'"
Elimination
Biliary levels of active antibiotic are several times higher
than serum levels. As the urinary levels are very low,
dosage schedules probably require no adjustment in
persons with renal impairment.'"
The bile and faeces are the main means of excretion.
The drug should probably be used with caution in per-
sons with hepatic failure, even though hepatic biotrans-
formation is minimal. The serum half-life of erythromycin
is 1 - 2 hours. Peak serum levels are attained 1 - 4 hours
after oral administration.
WHAT ADVERSE REACTIONS CAN BE
EXPECTED FROM ERYTHROMYCIN?
With the exception of the estolate, erythromycin is one of
the most innocuous antibacterial agents in use at present;
the reactions that do occur are very seldom serious, and
their incidence is very low. Gastro-intestinal side-effects
(nausea, epigastric discomfort or pain, vomiting, diar-
rhoea) are the most likely and are seldom severe. Allergic
reactions with or without pyrexia can occur with eosino-
philia and skin rash. Superinfection is a risk but is
generally considered to be less of a problem with the
narrow-spectrum antibacterial agents than with the broad-
spectrum agents.
The C'holestatic jaundice that occurs when the estolate
is used is the adverse reaction of concern. Tt has been
said that the incidence of tills problem in children under
the age of 12 years t& almost non-existent.'" However,
the incidence of overt jaundice in older patients has led
to certain restrictions on, or withdrawal of, the estolate de-
rivative in some countries. The problem is very rare with
shorter courses of the estolate. However, if it has occurred
once, its recurrence on re-exposure to the estolate seems
invariable. Subsequent use of the other forms of erythro-
mycin is without hazard.
Consistent clinical features of the syndrome are:
malaise, nausea, vomiting, and varying degrees of ab-
dominal pain, with low-grade fever and jaundice deve-
loping in about half of the individuals affected. A macu-
lopapular rash has been reported in about to°~ of patients.
The condition is generally associated with an increase
in serum concentrations of transaminase, alkaline phos-
phatase, bilirubin, and cholesterol. Eosinophilia is also
found in 50% of these patients. Prospective studies have
failed to demonstrate a relationsrup between the use of
the estolate and changes in blood chemistry which might
predict hepatotoxicity.""" Once medication is discontinued,
recovery is prompt and usually occurs within a week;
complete resolution is usual, but residual hepatic dys-
function has been reported ...·".
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The prompt recurrence of the syndrome in persons re-
exposed to the estolate suggests that the cholestasis re-
sults from some type of hypersensitivity reaction, although
details of the process are not known. It has been sug-
gested that the 2'-carbon ester linkage of the propionate
to the parent molecule is responsible for the toxicity.'"
It has, however, also been shown that substances with
strong detergent-like activity are capable of damaging
cells in culture, and that their detergent potency parallels
their hepatotoxicity.:n Thus it was found that erythro-
mycin cetyl sulphate was very hepatotoxic in humans
(which led to its rapid withdrawal from the pharma-
ceutical market) and that the detergent potency of this
form was even greater than that of the estolate.
In 1973, a report from the Australian Drug Evaluation
Committee concluded that 'current data demonstrate no
advantage in clinical efficacy for the estolate, but a clearly
increased risk of a specific reaction leading to a sig-
nificant morbidity in adults and older children.''' This
would seem to indicate the attitude that should be adopted
in 1978, until more definitive data become available to
show cause for a change of opinion.
IS DEVELOPMENT OF RESISTANCE A
PROBLEM WITH ERYTHROMYCIN?
Many textbooks and handbooks emphasize that the de-
velopment of resistance to erythromycin is a common
problem. However, it seems that de novo resistance of
bacteria normally susceptible to erythromycin is rare.
Strains with such resistance do occur, but invariably in
a hospital situation where no adequate antibiotic rotation
schedule exists, and where the antibiotic is widely used.
Under such circumstances, resistant strains are selected
and get passed from one patient to another. Moreover,
the opinion has been expressed that acquired resistance is
virtually unknown," and that in general practice, problems
with resistance are highly unlikely." The use of erythro-
mycin would not be expected to lead to the selection
of resistant E. coli, because E. coli do not possess factors
resistant to erythromycin. Thus the commensal E. coli in
the gut, the most common source of resistance factors,
would not be expected to cause this problem.
This author also states that the idea that bacteria
mutate to erythromycin resistance is probably erroneous,
and he doubts that mutation occurs, even with prolonged
use of the drug." A recent report"" based on findings in
general practice indicates that the incidence of resistance
to erythromycin among Staphylococcus aureus isolated
from throat swabs over a IS-month period was zero.
This was while erythromycin was being used as the treat-
ment of first choice for upper respiratory tract infections.
WHAT OF THE PARENTERAL
FORMULATIONS OF ERYTHROMYCIN?
For parenteral administration the following forms of
erythromycin are available: erythromycin ethylsuccinate
for intramuscular administration, and erythromycin lacto-
bionate for intravenous use. The intramuscular injection
is very painful and should definitely not be used in child-
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ren. The site of injection remains very tender for a long
time.
Erythromycin for intravenous administration gives rise
to local thrombophlebitis if not administered well diluted.
Physical incompatibilities in infusion therapy are enumer-
ated by the manufacturers, whose recommendations should
be closely followed. Recourse to parenteral intravenous
administration is warranted in exceptional circumstances.
WHAT DOSAGES OF ERYTHROMYCIN ARE
RECOMMENDED?
The usual adult dose is 1 - 4 g per day. The prolonged
effective tissue levels make a twice-a-day regimen quite
feasible. However, individual doses in excess of 500 mg
should be divided, so that a maximum of 500 mg is in-
gested as a single dose to minimize gastro-intestinal in-
tolerance. For children the usual oral dosage is 25 - 50
mg/kg/ d, divided so as to be administered 2 or 4 times
a day. For the management of rheumatic fever, the
dosage is 250 - 500 mg/d for children of a mass in excess
of 35 kg, and for those of lesser mass 125 - 250 mg/d.
For adults 250 - 500 mg/ d is recommended.
Uncontrolled trials suggest that for acne a maintenance
dose of 250 mg/ d is often adequate. The estolate should
be avoided for long-term treatment. As an alternative to
penicillin in the treatment of primary syphilis, 2 - 4 g/d
should be administered for 10 - 15 days.
Because antibiotics should never be prescri bed with-
out good cause, when they are prescribed they should be
administered in such a way as to ensure maximal efficacy.
Thus in order to ensure optimal bio-availability, it is
recommended that all forms of erythromycin be ad-
ministered in accordance with the package insert re-
commendations.
CONCLUSION
With the exception of the estolate derivative, erythro-
mycin is a very safe and non-toxic antibiotic that re-
commends itself for more widespread use, especially in
general practice. It is especially recommended for use
as a respiratory tract antibiotic. In practice, there would
seem to be little reason for making use of the potentially
hepatotoxic estolate. The parenteral forms should seldom
be necessary in general practice and the intramuscular
form is particularly painful.
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